The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®

mAbs

Volumn 8, Issue 7, 2016, Pages 1417-1424

  Ganguly, Bishu ^a   Balasa, Balaji ^a   Efros, Lyubov ^a   Hinton, Paul R ^a   Hartman, Stephen ^a   Thakur, Archana ^a   Xiong, Joanna M ^a   Schmidt, Brian ^a   Robinson, Randy R ^a   Sornasse, Thierry ^a   Vexler, Vladimir ^a   Sheridan, James P ^a  

^a ABBVIE INC   (United States)

Author keywords

Antibody dependent cell mediated cytotoxicity; CD16; CD25; complement dependent cytotoxicity; daclizumab; Fc gamma RIII; IL 2; multiple sclerosis; Zenapax

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; CD56 ANTIGEN; DACLIZUMAB; GLYCAN; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; OLIGOSACCHARIDE; IL2RA PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING CELL; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ION EXCHANGE CHROMATOGRAPHY; MOLECULAR INTERACTION; NATURAL KILLER CELL; PROTEIN PROCESSING; SURFACE PLASMON RESONANCE; COMPARATIVE STUDY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKOCYTES, MONONUCLEAR;

EID: 84988432803     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1207031     Document Type: Article

References (28)

1. T.A.Waldmann. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection:a 25-year personal odyssey. J Clin Immunol 2007; 27:1-18; PMID:17216565; http://dx.doi.org/10.1007/s10875-006-9060-0
2. B.Bielekova. Daclizumab therapy for multiple sclerosis. Neurotherapeutics 2013; 10:55-67; PMID:23055048; http://dx.doi.org/10.1007/s13311-012-0147-4
3. F.Vincenti, R.Kirkman, S.Light, G.Bumgardner, M.Pescovitz, P.Halloran, J.Neylan, A.Wilkinson, H.Ekberg, R.Gaston, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338:161-65; PMID:9428817; http://dx.doi.org/10.1056/NEJM199801153380304
4. R.Gold, G.Giovannoni, K.Selmaj, E.Havrdova, X.Montalban, E.W.Radue, D.Stefoski, R.Robinson, K.Riester, J.Rana, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT):a randomised, double-blind, placebo-controlled trial. Lancet 2013; 381:2167-75; PMID:23562009; http://dx.doi.org/10.1016/S0140-6736(12)62190-4
5. L.Kappos, H.Wiendl, K.Selmaj, D.L.Arnold, E.Havrdova, A.Boyko, M.Kaufman, J.Rose, S.Greenberg, M.Sweetser, et al. Daclizumab HYP vs. interferon β-1a in relapsing multiple sclerosis. N Engl J Med 2015; 373:1418-28; PMID:26444729; http://dx.doi.org/10.1056/NEJMoa1501481
6. J.P.Sheridan, R.R.Robinson, J.W.Rose. Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis. Expert Rev Clin Pharmacol 2014; 7:9-19; PMID:24308792; http://dx.doi.org/10.1586/17512433.2014.865516
7. J.F.McDyer, Z.Li, S.John, X.Yu, C.Y.Wu, J.A.Ragheb. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells:disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. J Immunol 2002; 169:2736-46; PMID:12193748; http://dx.doi.org/10.4049/jimmunol.169.5.2736
8. B.Bielekova, M.Catalfamo, S.Reichert-Scrivner, A.Packer, M.Cerna, T.A.Waldmann, H.McFarland, P.A.Henkart, R.Martin. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103:5941-46; PMID:16585503; http://dx.doi.org/10.1073/pnas.0601335103
9. J.T.Snyder, J.Shen, H.Azmi, J.Hou, D.H.Fowler, J.A.Ragheb. Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood 2007; 109:5399-406; PMID:17344465; http://dx.doi.org/10.1182/blood-2006-12-062943
10. J.S.Perry, S.Han, Q.Xu, M.L.Herman, L.B.Kennedy, B.Bielekova. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med 2012; 4:1-8; PMID:22855463; http://dx.doi.org/10.1126/scitranslmed.3004140
11. S.C.Wuest, J.H.Edwan, J.F.Martin, S.Han, J.S.Perry, C.M.Cartagena, E.Matsuura, D.Maric, T.A.Waldmann, B.Bielekova. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 2011; 17:604-09; PMID:21532597; http://dx.doi.org/10.1038/nm.2365
12. J.Stadlmann, M.Pabst, D.Kolarich, R.Kunert, F.Altmann. Analysis of immunoglobulin glycosylation by LC-ESIMS of glycopeptides and oligosaccharides. Proteomics 2008; 8:2858-71; PMID:18655055; http://dx.doi.org/10.1002/pmic.200700968
13. J.A.Bowles, S.Y.Wang, B.K.Link, B.Allan, G.Beuerlein, M.A.Campbell, D.Marquis, B.Ondek, J.E.Wooldridge, B.J.Smith, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006; 108:2648-54; PMID:16825493; http://dx.doi.org/10.1182/blood-2006-04-020057
14. J.N.Arnold, M.R.Wormald, R.B.Sim, P.M.Rudd, R.A.Dwek. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21-50; PMID:17029568; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141702
15. R.Jefferis. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012; 526:159-66; PMID:22465822; http://dx.doi.org/10.1016/j.abb.2012.03.021
16. H.H.Shi, C.T.Goudar. Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans. Biotechnol Bioeng. 2014 Oct;111(10):1907-19; PMID:24975601; http://dx.dpoi.org/10.1002/bit.25318.
17. B.Meibohm. Protein engineering for improved pharmacologic characteristics of established monoclonal antibody-based therapeutics. Clin Pharmacokinet 2014; 53:863-4; PMID:25212704; http://dx.doi.org/10.1007/s40262-014-0186-6
18. A.M.Goetze, Y.D.Liu, Z.Zhang, B.Shah, E.Lee, P.V.Bondarenko, G.C.Flynn. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011; 21:949-59; PMID:21421994; http://dx.doi.org/10.1093/glycob/cwr027
19. Y.Kanda, T.Yamada, K.Mori, A.Okazaki, K.Kitajima-Miyama, R.Kuni-Kamochi, R.Nakano, K.Yano, K.Shitara, M.Satoh. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides:the high-mannose, hybrid, and complex types. Glycobiology 2007; 17:104-18; PMID:17012310; http://dx.doi.org/10.1093/glycob/cwl057
20. O.Othman, J.Q.Tran, M.T.Tang, S.Dutta. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers:integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. Clin Pharmacokinet 2014; 53:907-18; PMID:25212703; http://dx.doi.org/10.1007/s40262-014-0159-9
21. H.Wiendl, C.C.Gross. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol 2013; 9:394-404; PMID:23732529; http://dx.doi.org/10.1038/nrneurol.2013.95
22. D.J.Huss, D.S.Mehta, A.Sharma, X.You, K.A.Riester, J.P.Sheridan, L.S.Amaravadi, J.S.Elkins, J.D.Fontenot. In vivo maintenance of human regulatory T cells during CD25 blockade. J Immunol 2015; 194:84-92; PMID:25416807; http://dx.doi.org/10.4049/jimmunol.1402140
23. J.D.Fontenot, J.P.Rasmussen, M.A.Gavin, A.Y.Rudensky. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6:1142-51; PMID:16227984; http://dx.doi.org/10.1038/ni1263
24. S.Sakaguchi, T.Yamaguchi, T.Nomura, M.Ono. Regulatory T cells and immune tolerance. Cell 2008; 133:775-87; PMID:18510923; http://dx.doi.org/10.1016/j.cell.2008.05.009
25. S.Z.Josefowicz, L.F.Lu, A.Y.Rudensky. Regulatory T cells:mechanisms of differentiation and function. Annu Rev Immunol 2012; 30:531-64; PMID:22224781; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141623
26. I.F.Amado, J.Berges, R.J.Luther, M.P.Mailhé, S.Garcia, A.Bandeira, C.Weaver, A.Liston, A.A.Freitas. IL-2 coordinates IL-2-producing and regulatory T cell interplay. J Exp Med 2013; 210:2707-20; PMID:24249704; http://dx.doi.org/10.1084/jem.20122759
27. G.Giovannoni, E.W.Radue, E.Havrdova, K.Riester, S.Greenberg, L.Mehta, J.Elkins. Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. J Neurol 2014; 261:316-23; PMID:24375015; http://dx.doi.org/10.1007/s00415-013-7196-4
28. T.Hori, T.Uchiyama, M.Tsudo, H.Umadome, H.Ohno, S.Fukuhara, K.Kita, H.Uchino. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 1987; 70:1069-72; PMID:3115332